(Reuters) - A highly anticipated new immunotherapy from Merck & Co Inc proved effective in patients with advanced melanoma as well as some with lung cancer or head and neck cancer, according to early-stage studies presented on Monday. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/ELpLqupGYwA/story01.htm
Read More
No comments:
Post a Comment